 | • レポートコード：TPM-NV195 • 出版社/出版日：Transparency Market Research / 2019年10月28日 • レポート形態：英文、PDF、213ページ • 納品方法：Eメール • 産業分類：製薬 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、喘息治療の世界市場について調べ、喘息治療の世界市場規模、市場動向、市場シェア、市場環境、市場予測、治療種類別（長期喘息、コントロール薬、クイックリリーフ（救助）薬）分析、投与経路別（吸入、経口、静脈内、皮下）分析、流通チャンネル別（小売薬局、病院薬局、オンライン薬局）分析、関連企業情報などをまとめました。 ・喘息治療の市場概要 ・喘息治療の市場動向 ・喘息治療の世界市場規模・予測 ・喘息治療市場：治療種類別（長期喘息、コントロール薬、クイックリリーフ（救助）薬） ・喘息治療市場：投与経路別（吸入、経口、静脈内、皮下） ・喘息治療市場：投与経路別（吸入、経口、静脈内、皮下） ・地域別分析（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争環境・関連企業分析 |
The global asthma treatment market will rise from a value of ~US$ 25.6 Bn in 2019 to ~US$ 30.5 Bn by 2027, and it is anticipated that an increase in the number of FDA-approved products in parallel to the increasing awareness among asthma patients regarding quality care will drive the steady odyssey of the market.
Analysts at Transparency Market Research (TMR) anticipate that, among the strategic approaches taken towards consolidation, partnerships and collaborations will remain integral to maximize profitability from new markets. Having witnessed product recalls, manufacturers in the asthma treatment market are dedicating ample efforts to develop high-quality products, which are likely to receive easy approvals from the FDA and similar regulatory bodies.
On the demand side, as awareness regarding quality care for the treatment of asthma increases among patients, the adoption of inhalers and oral drugs is likely to increase. However, in recent times, the cost-benefits of generic drugs have been appealing to patients, which could pose as a challenge for manufacturers in the asthma treatment market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Asthma Treatment Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Asthma Treatment Market Analysis and Forecast, 2017–2027
5. Market Outlook
5.1. Pipeline Analysis
5.2. Reimbursement Scenario
5.3. Disease Prevalence with Key Countries
6. Global Asthma Treatment Market Analysis and Forecasts, by Treatment Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Asthma Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
6.3.1. Long-term Asthma Control Medications
6.3.1.1. Inhaled Corticosteroids
6.3.1.2. Leukotriene Modifiers
6.3.1.3. Long-acting Beta Agonists
6.3.1.4. Combination Inhalers
6.3.1.5. Theophylline
6.3.1.6. Others (reslizumab, benralizumab, etc.)
6.3.2. Quick-relief (rescue) Medications
6.3.2.1. Short-acting Beta Agonists
6.3.2.2. Ipratropium (Atrovent)
6.3.2.3. Oral and Intravenous Corticosteroids
6.4. Global Asthma Treatment Market Attractiveness, by Treatment Type
7. Global Asthma Treatment Market Analysis and Forecasts, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Asthma Treatment Market Value (US$) Forecast, by Route of Administration, 2017–2027
7.3.1. Oral
7.3.2. Inhaled
7.3.3. Intravenous
7.3.4. Subcutaneous
7.4. Global Asthma Treatment Market Attractiveness, by Route of Administration
8. Global Asthma Treatment Market Analysis and Forecasts, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Asthma Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Global Asthma Treatment Market Attractiveness, by Distribution Channel
9. Global Asthma Treatment Market Analysis and Forecasts, by Region
9.1. Key Findings
9.2. Global Asthma Treatment Market Value (US$ Mn) Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Asthma Treatment Market Attractiveness, by Region
10. North America Asthma Treatment Market Analysis and Forecast
10.1. Introduction
10.2. North America Asthma Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
10.2.1. Long-term Asthma Control Medications
10.2.1.1. Inhaled Corticosteroids
10.2.1.2. Leukotriene Modifiers
10.2.1.3. Long-acting Beta Agonists
10.2.1.4. Combination Inhalers
10.2.1.5. Theophylline
10.2.1.6. Others (reslizumab, benralizumab, etc.)
10.2.2. Quick-relief (rescue) Medications
10.2.2.1. Short-acting Beta Agonists
10.2.2.2. Ipratropium (Atrovent)
10.2.2.3. Oral and Intravenous Corticosteroids
10.3. North America Asthma Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
10.3.1. Oral
10.3.2. Inhaled
10.3.3. Intravenous
10.3.4. Subcutaneous
10.4. North America Asthma Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. North America Asthma Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
10.5.1. U.S.
10.5.2. Canada
10.6. North America Asthma Treatment Market Attractiveness Analysis
10.6.1. By Treatment Type
10.6.2. By Route of Administration
10.6.3. By Distribution Channel
10.6.4. By Country/Sub-region
11. Europe Asthma Treatment Market Analysis and Forecast
11.1. Introduction
11.2. Europe Asthma Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
11.2.1. Long-term Asthma Control Medications
11.2.1.1. Inhaled Corticosteroids
11.2.1.2. Leukotriene Modifiers
11.2.1.3. Long-acting Beta Agonists
11.2.1.4. Combination Inhalers
11.2.1.5. Theophylline
11.2.1.6. Others (reslizumab, benralizumab etc.)
11.2.2. Quick-relief (rescue) Medications
11.2.2.1. Short-acting Beta Agonists
11.2.2.2. Ipratropium (Atrovent)
11.2.2.3. Oral and Intravenous Corticosteroids
11.3. Europe Asthma Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
11.3.1. Oral
11.3.2. Inhaled
11.3.3. Intravenous
11.3.4. Subcutaneous
11.4. Europe Asthma Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Europe Asthma Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region , 2017–2027
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Asthma Treatment Market Attractiveness Analysis
11.6.1. By Treatment Type
11.6.2. By Route of Administration
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Asthma Treatment Market Analysis and Forecast
12.1. Introduction
12.2. Asia Pacific Asthma Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
12.2.1. Long-term Asthma Control Medications
12.2.1.1. Inhaled Corticosteroids
12.2.1.2. Leukotriene Modifiers
12.2.1.3. Long-acting Beta Agonists
12.2.1.4. Combination Inhalers
12.2.1.5. Theophylline
12.2.1.6. Others (reslizumab, benralizumab etc.)
12.2.2. Quick-relief (rescue) Medications
12.2.2.1. Short-acting Beta Agonists
12.2.2.2. Ipratropium (Atrovent)
12.2.2.3. Oral and Intravenous Corticosteroids
12.3. Asia Pacific Asthma Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
12.3.1. Oral
12.3.2. Inhaled
12.3.3. Intravenous
12.3.4. Subcutaneous
12.4. Asia Pacific Asthma Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Asia Pacific Asthma Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region , 2017–2027
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Asthma Treatment Market Attractiveness Analysis
12.6.1. By Treatment Type
12.6.2. By Route of Administration
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Asthma Treatment Market Analysis and Forecast
13.1. Introduction
13.2. Latin America Asthma Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
13.2.1. Long-term Asthma Control Medications
13.2.1.1. Inhaled Corticosteroids
13.2.1.2. Leukotriene Modifiers
13.2.1.3. Long-acting Beta Agonists
13.2.1.4. Combination Inhalers
13.2.1.5. Theophylline
13.2.1.6. Others (reslizumab, benralizumab etc.)
13.2.2. Quick-relief (rescue) Medications
13.2.2.1. Short-acting Beta Agonists
13.2.2.2. Ipratropium (Atrovent)
13.2.2.3. Oral and Intravenous Corticosteroids
13.3. Latin America Asthma Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
13.3.1. Oral
13.3.2. Inhaled
13.3.3. Intravenous
13.3.4. Subcutaneous
13.4. Latin America Asthma Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Latin America Asthma Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region , 2017–2027
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Asthma Treatment Market Attractiveness Analysis
13.6.1. By Treatment Type
13.6.2. By Route of Administration
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Asthma Treatment Market Analysis and Forecast
14.1. Introduction
14.2. Middle East & Africa Asthma Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
14.2.1. Long-term Asthma Control Medications
14.2.1.1. Inhaled Corticosteroids
14.2.1.2. Leukotriene Modifiers
14.2.1.3. Long-acting Beta Agonists
14.2.1.4. Combination Inhalers
14.2.1.5. Theophylline
14.2.1.6. Others (reslizumab, benralizumab etc.)
14.2.2. Quick-relief (rescue) Medications
14.2.2.1. Short-acting Beta Agonists
14.2.2.2. Ipratropium (Atrovent)
14.2.2.3. Oral and Intravenous Corticosteroids
14.3. Middle East & Africa Asthma Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
14.3.1. Oral
14.3.2. Inhaled
14.3.3. Intravenous
14.3.4. Subcutaneous
14.4. Middle East & Africa Asthma Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Middle East & Africa Asthma Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region , 2017–2027
14.5.1. GCC
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Asthma Treatment Market Attractiveness Analysis
14.6.1. By Treatment Type
14.6.2. By Route of Administration
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Share Analysis, by Company (2018)
15.2. Company Profiles
15.2.1. AstraZeneca
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Company Financials
15.2.1.3. Growth Strategies
15.2.1.4. SWOT Analysis
15.2.2. Boehringer Ingelheim International GmbH
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Company Financials
15.2.2.3. Growth Strategies
15.2.2.4. SWOT Analysis
15.2.3. GlaxoSmithKline plc
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Company Financials
15.2.3.3. Growth Strategies
15.2.3.4. SWOT Analysis
15.2.4. Novartis AG
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Company Financials
15.2.4.3. Growth Strategies
15.2.4.4. SWOT Analysis
15.2.5. Teva Pharmaceutical Industries Ltd
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Company Financials
15.2.5.3. Growth Strategies
15.2.5.4. SWOT Analysis
15.2.6. Sumitomo Dainippon Pharma Co., Ltd
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Company Financials
15.2.6.3. Growth Strategies
15.2.6.4. SWOT Analysis
15.2.7. Merck & Co., Inc.
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Company Financials
15.2.7.3. Growth Strategies
15.2.7.4. SWOT Analysis
15.2.8. F. Hoffmann-La Roche Ltd.
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Company Financials
15.2.8.3. Growth Strategies
15.2.8.4. SWOT Analysis
15.2.9. Sanofi
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Company Financials
15.2.9.3. Growth Strategies
15.2.9.4. SWOT Analysis
15.2.10. Mylan N.V.
15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.10.2. Company Financials
15.2.10.3. Growth Strategies
15.2.10.4. SWOT Analysis